PTC Therapeutics (PTCT) FY23 Revenue Guidance Tops Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference
January 9, 2023 9:15 AM EST-Â ~$710 million unaudited 2022 total revenue, representing an impressive over 30% year-over-year growth
-Â $940 million - $1.0 billion 2023 total revenue guidance
-Â Results from three registration-directed clinical trials expected in 2023
-Â One additional registration-directed clinical trial expected to initiate in 2023
SOUTH PLAINFIELD, N.J., Jan. 9, 2023 /PRNewswire/ --Â PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 41st Annual J.P. Morgan Healthcare... More
